SCHEMBL2396759

SCHEMBL2396759

Cc1cc(Nc2nc(C)c(-c3ccc(Cl)c(S(=O)(=O)NCCO)c3)s2)n(C)n1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 10/20 0.67
PIK3CG P48736 9/20 0.67
PI4KB Q9UBF8 6/20 0.67
PIK3C3 Q8NEB9 4/20 0.67
PIK3CA P42336 3/20 0.67
PIK3CB P42338 2/20 0.67
PIK3C2A O00443 1/20 0.67
PIK3C2B O00750 1/20 0.67
PI4KA P42356 1/20 0.67
PRKDC P78527 1/20 0.67
USP2 O75604 1/20 0.42
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
PDE4D Q08499 1/20 0.39
PDE7A Q13946 1/20 0.39
GSTO1 P78417 1/20 0.38
MAPT P10636 2/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2393804 0.84 PIK3CD (0.67) PIK3CDPIK3CGPI4KBPIK3C3PIK3CA
SCHEMBL2396076 0.82 PIK3CD (0.72) PIK3CDPIK3CGPI4KBPIK3C3PIK3CA
SCHEMBL2397554 0.81 PIK3CD (0.70) PIK3CDPIK3CGPI4KBPIK3C3PIK3CA
SCHEMBL48649 0.81 PIK3CD (1.00) PIK3CDPIK3CGPI4KBPIK3C3PIK3CA
SCHEMBL21096715 0.81 PIK3CD (0.75) PIK3CDPIK3CGPI4KBPIK3C3PIK3CA
SCHEMBL29373332 0.81 PIK3CD (1.00) PIK3CDPIK3CGPI4KBPIK3C3PIK3CA
SCHEMBL2396778 0.80 PIK3CD (0.68) PIK3CDPIK3CGPI4KBPIK3C3PIK3CA
SCHEMBL2400053 0.80 PIK3CD (0.68) PIK3CDPIK3CGPI4KBPIK3C3PIK3CA
SCHEMBL48680 0.76 PIK3CD (0.57) PIK3CDPIK3CGPI4KBPIK3C3PIK3CA
SCHEMBL14851611 0.70 PIK3CG (0.72) PIK3CDPIK3CGPI4KBPIK3C3PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8017608-B2 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2011-09-13 US disclosed
EP-1608647-B1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-09 EP disclosed
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors NOVARTIS AG (CH) 2006-07-06 US disclosed
EP-1608647-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS Novartis AG (CH) 2005-12-28 EP disclosed
WO-2004078754-A1 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS NOVARTIS AG (CH) 2004-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148822-A1 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors MAP3K13, AKT3, MAP3K3 PIK3CD 42/4885PIK3CG 49/4885PI4KB 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.